[Chimeric antigen receptors in oncology: clinical applications and new developments]

Alexander Michels1, Jessica Hartmann1, Christian J Buchholz2

  • 1Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225, Langen, Deutschland.

Insights

Chimeric antigen receptor (CAR) T and NK cell therapies show promise for advanced cancers like lymphoma and leukemia. Ongoing research aims to overcome side effects and manufacturing challenges for broader application.

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Two novel chimeric antigen receptor (CAR) T-cell therapies received EU marketing authorization in 2018 for advanced lymphoma and leukemia.
  • These groundbreaking treatments garnered significant attention due to their innovative mechanisms, efficacy, severe side effects, and manufacturing complexities.

Purpose of the Study:

  • To describe the mode of action for CAR T and CAR NK cells.
  • To review the current clinical trial landscape and early real-world data for CAR therapies.
  • To summarize preclinical findings on CAR T-cell therapy side effects and discuss potential solutions to current limitations.

Main Methods:

  • Review of clinical trial data and real-world evidence for CAR T and CAR NK cell therapies.
  • Analysis of preclinical studies investigating the mechanisms of CAR T-cell therapy side effects.
  • Discussion of challenges and potential solutions in CAR technology development and application.

Main Results:

  • Hundreds of active clinical trials worldwide highlight the rapid advancement and global interest in CAR technology.
  • Preclinical models are beginning to elucidate the mechanisms behind severe side effects associated with CAR T-cell therapy.
  • Early real-world data and ongoing clinical trials are crucial for understanding the therapeutic potential and limitations of CAR technology.

Conclusions:

  • CAR T and CAR NK cell therapies represent a significant advancement in cancer treatment, particularly for aggressive hematological malignancies.
  • Addressing side effects and manufacturing hurdles is critical for expanding the use of CAR technology.
  • CAR technology holds the potential to evolve from last-line treatment to a broadly effective standard of care for various tumor types.

Related Concept Videos